TELA Bio (NASDAQ:TELA) & PAVmed (NASDAQ:PAVM) Head-To-Head Review

TELA Bio (NASDAQ:TELAGet Free Report) and PAVmed (NASDAQ:PAVMGet Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Insider and Institutional Ownership

94.3% of TELA Bio shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 4.7% of TELA Bio shares are owned by insiders. Comparatively, 7.3% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares TELA Bio and PAVmed”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TELA Bio $71.22 million 0.89 -$46.66 million ($1.41) -1.14
PAVmed $1.99 million 5.36 -$64.18 million $0.71 0.88

TELA Bio has higher revenue and earnings than PAVmed. TELA Bio is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

TELA Bio has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, PAVmed has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for TELA Bio and PAVmed, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TELA Bio 0 1 3 0 2.75
PAVmed 0 0 1 0 3.00

TELA Bio presently has a consensus price target of $7.25, suggesting a potential upside of 350.31%. PAVmed has a consensus price target of $19.00, suggesting a potential upside of 2,939.03%. Given PAVmed’s stronger consensus rating and higher probable upside, analysts plainly believe PAVmed is more favorable than TELA Bio.

Profitability

This table compares TELA Bio and PAVmed’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TELA Bio -60.49% -556.18% -63.13%
PAVmed 602.97% N/A -92.36%

Summary

PAVmed beats TELA Bio on 9 of the 14 factors compared between the two stocks.

About TELA Bio

(Get Free Report)

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

About PAVmed

(Get Free Report)

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.